Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) is a clinical-stage gene editing company focused on developing in vivo therapies using its proprietary ARCUS platform. The company reported for the quarterly period ended September 30, 2024. During this period, the company continued to divest from its historical CAR T cell therapy operations (classified as discontinued operations) to focus exclusively on its ARCUS genome editing programs, including PBGENE-HBV (hepatitis B) and PBGENE-3243 (mitochondrial disease).
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $576 | $13,120 | $68,058 | $41,689 |
| Operating Expenses | $21,851 | $25,483 | $69,374 | $70,535 |
| Operating Loss | $(21,275) | $(12,363) | $(1,316) | $(28,846) |
| Net Income (Loss) | $(16,425) | $(8,079) | $24,912 | $(45,030) |
| Cash and Cash Equivalents | $98,752 | N/A | N/A | N/A |
| Restricted Cash | $22,576 | N/A | N/A | N/A |
| Total Debt (Principal) | $22,500 | $22,500 | N/A | N/A |
Note: Q3 2023 Net Loss includes income from discontinued operations of $4.0 million. 9M 2024 Net Income is significantly influenced by a $21.8 million non-cash gain on the change in fair value of warrant liabilities.
Material Changes vs. Prior Period
- Revenue Volatility: Q3 2024 revenue dropped to $0.6 million from $13.1 million in Q3 2023, primarily due to the termination of the Prevail Therapeutics agreement in April 2024 and the near-completion of pre-clinical work under the Novartis agreement. However, for the nine months ended September 30, 2024, revenue increased to $68.1 million (from $41.7 million in 2023) driven by the recognition of remaining revenue from the Prevail agreement and new revenue from the TG Therapeutics license.
- Profitability Drivers: The company reported a net income of $24.9 million for the nine months ended September 30, 2024, compared to a net loss of $45.0 million in the prior year. This turnaround is largely attributable to a $21.8 million non-cash gain from the change in fair value of warrant liabilities issued in March 2024, rather than operational profitability.
- Debt Restructuring: In July 2024, the company replaced its revolving line of credit with a $22.5 million term loan (2024 Term Loan) maturing in June 2027. This required the company to maintain $22.6 million in restricted cash as collateral.
- Operating Expenses: Operating expenses decreased slightly in Q3 2024 compared to Q3 2023 ($21.9M vs $25.5M) due to reduced headcount and lower consulting fees, though R&D costs for specific programs (PBGENE-3243) increased.
Guidance, Outlook, and Risks
- Liquidity and Runway: Management believes existing cash ($98.8 million) and restricted cash ($22.6 million), combined with expected operational receipts and ATM facility availability, are sufficient to fund operations into the second half of 2026. This runway is expected to support first-in-human Phase 1 clinical data for two wholly-owned programs.
- Program Updates:
- PBGENE-HBV: Received CTA approval in Moldova; working towards patient dosing.
- PBGENE-3243: Preclinical data presented; IND/CTA submission expected in 2025.
- TG Therapeutics: Partner received FDA clearance for an IND to investigate azer-cel for multiple sclerosis; Phase 1 trial anticipated in 2024.
- Key Risks:
- Capital Needs: The company has an accumulated deficit of $464.7 million and expects to continue incurring losses. Failure to raise additional capital could force delays in research programs.
- Regulatory Uncertainty: As a novel technology, ARCUS faces a rigorous and evolving regulatory landscape. Clinical trial outcomes are uncertain.
- Warrant Liability: The company has $10.6 million in warrant liabilities subject to remeasurement, which can cause significant volatility in reported net income/loss.
- Debt Covenants: The 2024 Term Loan includes covenants restricting mergers, additional indebtedness, and requiring the maintenance of the restricted cash balance.
Investor Verification Checklist
- Warrant Liability Impact: Verify the extent to which the reported net income for the nine months ended September 30, 2024, is driven by the non-cash gain on warrant liability remeasurement rather than core operations.
- Restricted Cash: Confirm the liquidity status of the $22.6 million restricted cash balance, which is pledged as collateral for the term loan and unavailable for general operations.
- Revenue Sustainability: Assess the sustainability of revenue streams following the termination of the Prevail agreement and the recognition of the bulk of that contract's revenue in the first half of 2024.
- Cash Burn Rate: Monitor the net cash used in operating activities ($39.8 million for 9M 2024) against the current cash balance to validate the management's "second half of 2026" runway estimate.
- Debt Terms: Review the specific covenants of the 2024 Term Loan, particularly the requirement to maintain the cash security account and restrictions on refinancing.